The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

Author Mari, Jair de Jesus Autor UNIFESP Google Scholar
Lima, Mauricio Silva de Autor UNIFESP Google Scholar
Costa, Anna Maria Niccolai Autor UNIFESP Google Scholar
Alexandrino, Neusa Google Scholar
Rodrigues-Filho, Salomao Google Scholar
Oliveira, Irismar Reis de Google Scholar
Tollefson, Gary D. Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Fed Univ Pelotas
Catholic Univ Pelotas
Hosp Anna Rech
Pax Clin Psiquiatrica Goiania
Universidade Federal da Bahia (UFBA)
Abstract Aims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.
Keywords schizophrenia
Tardive dyskinesia
randomized controlled trial
olanzapine
typical antipsychotic
Language English
Date 2004-12-01
Published in European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004.
ISSN 0940-1334 (Sherpa/Romeo, impact factor)
Publisher Dr Dietrich Steinkopff Verlag
Extent 356-361
Origin http://dx.doi.org/10.1007/s00406-004-0514-1
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000226092900002
URI http://repositorio.unifesp.br/11600/43579

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account